NCT05310058CompletedNot Applicable
A Randomized, Parallel Study to Assess the Pharmacokinetics of C6 Ketone Di-ester in Healthy Adults
BHB Therapeutics, Ireland LTD2 sites in 1 country34 target enrollmentStarted: April 11, 2022Last updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 34
- Locations
- 2
- Primary Endpoint
- Area under the curve (AUC)
Study Overview
Brief Summary
Randomized, parallel repeat dose pharmacokinetic study of C6 ketone di-ester in a ready to drink beverage matrix.
Detailed Description
Recruiting 33 healthy adults to participate in a pharmacokinetic (PK) study of C6 ketone di-ester in a ready to drink beverage matrix. Following randomization, subjects will participate in a full day of PK sample collection prior to being sent home with study product for 1 week. After 1 week of daily consumption, subjects will return to the clinic for a second PK study identical to the first. Blood samples will be collected for 8 hours following test product consumption on both PK days.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Basic Science
- Masking
- Single (Outcomes Assessor)
Masking Description
Bioanalytics and biostatistics services will be blinded to treatment identity until after the database has been locked and all analysis is complete.
Eligibility Criteria
- Ages
- 18 Years to 65 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Subject has a BMI 18.5-34.99 kg/m2 (inclusive)
- •Subject is willing to consume the study beverage daily starting on Day 0 through Day 7 following taste testing at Visit 1
- •Subject is not a smoker and has no plans to change his/her usage of the following products throughout the study period: tobacco, smoking products (including, but not limited to cigarettes, cigars, chewing tobacco, e-cigarettes), and nicotine products (e.g., nicotine gum and/or nicotine patches)
- •Subject is a non-user or former user (cessation ≥3 months) of any marijuana or hemp products and has no plans to use marijuana or hemp products during the study period. No washout is required for topical marijuana or hemp products, but subjects are required to abstain from these products during the study period.
- •Subject is willing and able to comply with all study procedures including overnight fasting (12 ± 2 h, water only), maintenance of usual body weight, avoidance of foods or supplements that increase ketone production in the body throughout the entire study period, avoidance of vigorous exercise (moderate habitual exercise is allowed) with the exception of the 24 h prior to Visits 2 and 3 (Days 0 and 7) when subjects must avoid exercise completely
- •Subjects is willing to abstain from caffeine during Visits 2 and 3 (Days 0 and 7).
- •Subject has a score of 7 to 10 on the Vein Access Scale
- •Subject is willing and able to comply with the visit schedule.
- •Subject has no health conditions that would prevent him/her from fulfilling the study requirements as judged by the Clinical Investigator on the basis of medical history, physical examination findings, and routine laboratory test results.
- •Subject understands the study procedures and signs forms providing informed consent to participate in the study and authorizes the release of relevant protected health information to the Clinical Investigator.
Exclusion Criteria
- •Subject has a known allergy, intolerance, or sensitivity to any of the ingredients in the study beverages and all other foods/beverages provided in this study, including soy, milk, and peanut.
- •Subject has extreme dietary habits (e.g., intermittent fasting or time restricted eating, Atkins diet, vegan, very high protein/low carbohydrate)
- •Subject has used weight-loss medications (including over-the-counter medications and/or supplements) or participated in weight loss programs
- •Unstable use of any prescription medications is not allowed.
- •Subject has used ketone supplements (ketone salts or esters, and medium chain triglycerides [MCT]) within 30 days
- •Subject has been exposed to any non-registered drug product within 30 days of Visit 1
- •Subject has a history or presence of clinically important endocrine (including hyperparathyroidism, type 1 or 2 diabetes mellitus and/or hypoglycemia), cardiovascular (including, but not limited to history of myocardial infarction, peripheral arterial disease, stroke), pulmonary (including uncontrolled asthma), hepatic, renal, gastrointestinal, hematologic, immunologic, dermatologic, rheumatic (including gout), and/or biliary condition(s), that, in the opinion of the Clinical Investigator (has MD qualifications), could interfere with the interpretation of the study results.
- •Subject has a history of bariatric surgery for weight reducing purposes
- •Subject has a history or presence of cancer in the prior two years, except for non-melanoma skin cancer.
- •Subject has an abnormal laboratory test result(s) of clinical importance at Visit 1 (Day -7), at the discretion of the Clinical Investigator. One re-test will be allowed on a separate day prior to Visit 2 (Day 0), for subjects with abnormal laboratory test results.
- •Subject has any signs or symptoms of an active infection of clinical relevance (e.g., urinary tract or respiratory) within 5 days of Visit 2 (Day 0). If an infection occurs during the study period, test visits should be rescheduled until all signs and symptoms have resolved (at the discretion of the Clinical Investigator) and any treatment (e.g., antibiotic therapy) has been completed at least 5 days prior to testing.
- •Subject has experienced any major trauma or any other surgical event within three months
Outcomes
Primary Outcomes
Area under the curve (AUC)
Time Frame: 0 - 8 hours
AUC of circulating metabolites in blood
Cmax
Time Frame: 0 - 8 hours
Maximum concentration of circulating metabolites in blood
Tmax
Time Frame: 0 - 8 hours
Time to maximum concentration of circulating metabolites in blood
Elimination half-life
Time Frame: 0-8 hours
Time required to reduce metabolite concentration by 50%
Secondary Outcomes
No secondary outcomes reported
Investigators
Study Sites (2)
Loading locations...
Similar Trials
Completed
Not Applicable
Pharmacokinetics of Two Fatty Acid Ketone EstersPharmacokineticsNCT05686083BHB Therapeutics, Ireland LTD12
Withdrawn
Phase 1
Phase 1 Dexlansoprazole Delayed-Release Capsules for Acid-Related Disorders in Infants Aged 1 to 11 MonthsPediatric Gastroesophageal Reflux DiseaseNCT02442752Takeda
Completed
Phase 1
To Evaluate the Safety, Tolerability and Pharmacokinetics of K0706 in Plasma and Cerebrospinal Fluid in Healthy VolunteersHealthyNCT03445338Sun Pharma Advanced Research Company Limited18
Active, not recruiting
Phase 2
Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid SyndromeCarcinoid SyndromeCarcinoid TumorCarcinoid Tumor of IleumCarcinoid Tumor of CecumCarcinoid Syndrome DiarrheaCarcinoid Intestine TumorCarcinoid Tumor of LiverCarcinoid Tumor of PancreasCarcinoidNCT05361668Crinetics Pharmaceuticals Inc.36
Completed
Phase 3
BE Study Budesonide 80 μg and Formoterol Fumarate Dihydrate 4.5 μg Inhalation Product in Asthma PatientAsthmaNCT05322707Cipla Ltd.1,485